Every parliamentary written question tabled by Mark Francois this session, with the full answer and department. See how every department answers, or back to the MP page.
Showing 601–603 of 603 · this parliament
Whether the evaluation of non-specific pathways will include granular blood cancer data.
Raising awareness, delivering more research, including into new treatments, and improving early diagnosis of cancers, which includes blood related cancers such as leukaemia, are crucial for improving cancer survival.NHS England has implemented non-symptom...
What assessment he has made of the adequacy of five-year survival rates for (a) acute myeloid leukaemia and (b) other leukaemias.
The age-standardised, one-year net survival for adults, those aged 15 to 99 years old, diagnosed with leukaemia between 2016 and 2020 in England was 74.4%, and the five-year survival rate was 55.9%.NHS England has implemented non symptom specific pathways for patients who present with non-specific symptoms or combinations thereof, that can indicate several different cancers. This includes leukaemia, which can present non-specific symptoms, such as unexpected weight loss and night sweats. The national evaluation showed that blood cancers are one of the most common cancer types diagnosed through these pathways.Raising awareness, delivering more research, including into new treatments, and improving early diagnosis of cancers, which includes blood related cancers such as leukaemia, are crucial for improving cancer survival.Cancer patients are being failed, waiting too long for a diagnosis and treatment. We will bring down waits for cancer appointments with the Fit For the Future fund, doubling the number of state-of-the-art magnetic resonance imaging and computed tomography in the National Health Service to ensure early diagnosis and faster treatment.
What steps his Department is taking to ensure consistent publication of data on waiting times for (a) leukaemia and (b) other cancer treatments.
Cancer waiting time data is collected by NHS England according to three performance standards: the Faster Diagnosis Standard (FDS), which aims to ensure patients have cancer diagnosed or ruled out within 28 days of referral from a general practice or screening service; the 31-day wait from a decision to treat to first or subsequent treatment of cancer combined standard; and the 62-day referral to first definitive treatment for cancer combined standard. Data can then be broken down by cancer type. For the FDS, data regarding leukaemia and its sub-types is collected using the following two categories, suspected acute leukaemia and suspected haematological malignancies, excluding acute leukaemia. The latter category includes non-acute leukaemia when there is a suspicion. These statistics are published monthly and are available at the following link: https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/